DiaMedica Inc. | Balance Sheet

Fiscal year is January-December. All values CAD Thousands.
2013
2014
2015
2016
2017
Cash & Short Term Investments
2,684.50
236.60
229.90
2,328.50
1,704.30
Total Accounts Receivable
15.30
9.80
13.30
69.70
107.40
Other Current Assets
87.00
62.50
45.60
87.50
79.90
Total Current Assets
2,786.70
308.80
288.80
2,485.70
1,891.60
Net Property, Plant & Equipment
20.90
18.10
19.80
26.00
47.00
Total Investments and Advances
-
-
-
-
339.60
Intangible Assets
286.70
-
-
-
-
Total Assets
3,094.40
326.90
308.60
2,511.70
2,278.20
ST Debt & Current Portion LT Debt
-
-
363.10
268.80
-
Accounts Payable
396.20
1,114.40
-
-
-
Other Current Liabilities
1,227.10
987.30
1,113.00
572.00
1,144.50
Total Current Liabilities
1,623.30
2,101.70
1,476.10
840.80
1,144.50
Long-Term Debt
-
-
538.70
-
-
Other Liabilities
-
-
-
-
141.40
Total Liabilities
1,623.30
2,101.70
2,014.80
840.80
1,285.90
Common Equity (Total)
1,471.10
1,774.80
1,706.20
1,670.90
992.30
Total Shareholders' Equity
1,471.10
1,774.80
1,706.20
1,670.90
992.30
Total Equity
1,471.10
1,774.80
1,706.20
1,670.90
992.30
Liabilities & Shareholders' Equity
3,094.40
326.90
308.60
2,511.70
2,278.20

About DiaMedica

View Profile
Address
2 Carlson Parkway North
Minneapolis Minnesota 55447
United States
Employees -
Website http://www.diamedica.com
Updated 09/14/2018
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. Its products includes DM199 that focused on acute ischemic stroke, and chronic kidney disease; and KLK1 which plays a critical role in the regulation of local blood flow, vasodilation in the body, inflammation, and oxidative stress. The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.